Table 10.

Clinical trials of other drug conjugates for lung cancer treatment

Drug name	Target	NCT number	Status	Study phase	Number of subjects	Primary endpoint	Study start date
PEN-866	Hsp90	NCT03221400	Recruiting	I/II	340	DLTs	Aug 2017
EC1456	FR	NCT01999738	Completed (NA)	I	93	Not provided	Oct 2013
MBC-11	Ca +	NCT02673060	Completed (NA)	I	18	AEs	Nov 2015
CBP-1008	TRPV6	NCT04740398	Recruiting	I	143	AEs	Mar 2019
Vintafolide	EGFR	NCT02049281	Terminated	I	3	Cmax	May 2014
Vintafolide	EGFR	NCT01688791	Terminated	I	37	DLTs	Sep 2014
Vintafolide	EGFR	NCT01002924	Completed (NA)	II	1	AEs	Dec 2009
Vintafolide	EGFR	NCT00511485	Completed (NA)	II	43	Clinical benefit	Jul 2009
Vintafolide	EGFR	NCT00308269	Completed (NA)	I	32	MTD	Aug 2007
Vintafolide	EGFR	NCT01577654	Completed (NA)	II	203	PFS	Dec 2013
BMS-753493	–	NCT00546247	Terminated	I/II	26	MTD	Mar 2010
BMS-753493	–	NCT00550017	Terminated	I/II	39	MTD	Dec 2007
EC0489	FR	NCT00852189	Completed (NA)	I	65	MTD	Dec 2011
EC0225	–	NCT00441870	Completed (NA)	I	77	MTD	Feb 2007
ACE1702	HER2	NCT04319757	Recruiting	I	36	AEs	May 2020
SBT6050	HER2	NCT04460456	Not recruiting	I	58	DLTs	Jul 2020
SBT6050	HER2	NCT05091528	Terminated	I/II	2	DLTs	Feb 2022
SBT6290	Nectin4	NCT05234606	Withdrawn	I/II	0	DLTs	Mar 2022
BDC-1001	Toll	NCT04278144	Recruiting	I/II	390	AEs	Feb 2020
XMT-2056	STING	NCT05514717	Suspended	I	171	DLTs	Jan 2021
ADCT-301	Treg cells	NCT03621982	Terminated	I	78	AEs	Nov 2018
ORM-5029	HER2	NCT05511844	Recruiting	I	87	MTD	Oct 2022

DLT dose-limiting toxicity, MTD maximum tolerated dose, AE adverse event, Cmax maximum plasma concentration, PFS progression free survival